Lexicon Pharms Inc Company Profile

What is the competitive landscape for LEXICON PHARMS INC

LEXICON PHARMS INC has one approved drug.

There are three US patents protecting LEXICON PHARMS INC drugs.

There are seventy-one patent family members on LEXICON PHARMS INC drugs in thirty-three countries and twelve supplementary protection certificates in eleven countries.

Summary for Lexicon Pharms Inc

International Patents:	71
US Patents:	3
Tradenames:	1
Ingredients:	1
NDAs:	1

Drugs and US Patents for Lexicon Pharms Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lexicon Pharms Inc	INPEFA	sotagliflozin	TABLET;ORAL	216203-002	May 26, 2023		RX	Yes	Yes	8,217,156		Y	Y
Lexicon Pharms Inc	INPEFA	sotagliflozin	TABLET;ORAL	216203-001	May 26, 2023		RX	Yes	No	8,476,413		Y	Y
Lexicon Pharms Inc	INPEFA	sotagliflozin	TABLET;ORAL	216203-001	May 26, 2023		RX	Yes	No	8,217,156		Y	Y
Lexicon Pharms Inc	INPEFA	sotagliflozin	TABLET;ORAL	216203-002	May 26, 2023		RX	Yes	Yes	7,781,577		Y	Y
Lexicon Pharms Inc	INPEFA	sotagliflozin	TABLET;ORAL	216203-002	May 26, 2023		RX	Yes	Yes	8,476,413		Y	Y

International Patents for Lexicon Pharms Inc Drugs

Country	Patent Number	Estimated Expiration
Poland	2089361
Japan	6283337
World Intellectual Property Organization (WIPO)	2008109591
Eurasian Patent Organization	200970337
Poland	2308841

Supplementary Protection Certificates for Lexicon Pharms Inc Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2089361	1990043-0	Sweden		PRODUCT NAME: SOTAGLIFLOZIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/19/1363 20190430
2089361	2019/044	Ireland		PRODUCT NAME: SOTAGLIFLOZIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/19/1363 20190430
2089361	SPC/GB19/054	United Kingdom		PRODUCT NAME: SOTAGLIFLOZIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: UK EU/1/19/1363 (NI) 20190430; UK PLGB 53567/0001 20190430
2089361	301003	Netherlands		PRODUCT NAME: SOTAGLIFLOZIN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/19/1363 20190430
2089361	CR 2019 00042	Denmark		PRODUCT NAME: SOTAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/19/1363 20190430

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Lexicon Pharms Inc

Pharmaceutical Competitive Landscape Analysis: Lexicon Pharmaceuticals Inc – Market Position, Strengths & Strategic Insights

Last updated: February 19, 2026

What is Lexicon Pharmaceuticals Inc.’s current market position?

Lexicon Pharmaceuticals Inc. operates primarily within the therapeutic areas of immunology, metabolic diseases, and oncology, focusing on small-molecule and gene-based therapies. As of 2023, its core marketed product is Xermelo (telotristat ethyl), approved for carcinoid syndrome diarrhea. The company holds a niche position with revenues around $173 million in 2022, driven mainly by Xermelo sales, which account for approximately 80% of total revenue[1].

Market influence extends into late-stage pipeline candidates and licensing agreements designed to expand its portfolio. Its share in the global pharmaceutical market remains limited but targeted, with established presence in specific indications and regions.

How does Lexicon compare to key competitors?

Company	Focus Area	Revenue (2022)	Main Product(s)	R&D Pipeline	Strategic Alliances
Lexicon Pharmaceuticals	Rare diseases, immunology, metabolic disorders	$173 million	Xermelo	Several late-stage assets in fibrosis, oncology	Partnered with Sanofi for Xermelo and others
Deciphera Pharmaceuticals	Oncology, rare tumor types	$271 million	Qinlock (ripretinib)	Multiple kinase inhibitors	Strategic acquisitions, licensing deals
Ipsen	Oncology, neuroscience, rare diseases	$2.4 billion	Decapeptyl, Onivyde	Gene therapies, biosimilars	Acquisitions to diversify portfolio
Genentech (Roche)	Oncology, immunology	$75 billion	Rituxan, Tecentriq	Multiple biosimilars, targeted therapies	Extensive biotech partnerships

Lexicon maintains a niche strategy, focusing on specialized, high-need indications with limited but well-defined market segments. This contrasts with larger players like Ipsen and Roche, which have broader portfolios and higher revenues.

What are Lexicon's core strengths?

• Specialized Market Focus: Targeting rare and unmet medical needs, such as carcinoid syndrome, allows Lexicon to maintain pricing power and minimal competition.

• Innovative Molecules: Telotristat ethyl is the only approved drug and demonstrates a sustained revenue stream, with potential for label expansion.

• Strategic Partnerships: Collaboration with Sanofi accelerates development, market access, and distribution channels, reducing the need for extensive internal infrastructure.

• Pipeline Potential: Ongoing clinical trials in fibrosis and immunology could diversify revenue and strengthen its therapeutic influence.

What strategic insights can be derived from Lexicon’s positioning?

• Focus on Niche Market Expansion: Prioritize developing label extensions for Xermelo and advancing pipeline projects that address orphan diseases and unmet needs.
• Leverage Partnerships for Global Reach: Deepen alliances with major pharma entities to access new markets, especially in regions with limited Lexicon presence.
• Invest in Pipeline Diversification: Allocate R&D resources toward high-impact indications such as fibrotic diseases, where late-stage competitors show increasing activity.
• Potential Acquisition Targets: Identify small biotech firms with complementary assets to expand the pipeline and technological capabilities without large internal R&D expenses.

What are the risks impacting Lexicon’s market position?

• Limited Revenue Base: Heavy dependence on Xermelo exposes Lexicon to market decline risks if generics or new competitors emerge.
• Pipeline Uncertainty: Clinical trial failures or delays could hinder growth prospects.
• Market Access Barriers: Pricing pressures and reimbursement hurdles in key markets could limit revenue potential.
• Competitive Loss of Niche Indications: Larger pharma companies increasing focus on diagnostic and treatment options for carcinoid syndrome might erode Lexicon’s market share.

How does regulatory landscape affect Lexicon’s strategic options?

• FDA and EMA approvals: Stricter approval processes and post-market surveillance requirements necessitate thorough clinical validation, potentially delaying pipeline progress.
• Orphan drug designations: These provide market exclusivity extending up to 7 years in the US, encouraging investment in rare diseases.
• Pricing and reimbursement policies: Increasing scrutiny on drug prices in US and European markets could influence pricing strategies, especially for niche therapeutics.

What are the key takeaways?

• Lexicon maintains a focused niche within rare and specialized diseases, with a stable revenue base driven by Xermelo.
• Its strategic partnerships and pipeline indicate ongoing expansion opportunities, provided clinical development timelines are met.
• Competition exists primarily from larger, diversified biotech and pharma firms targeting similar indications or broader markets.
• Diversification beyond its core product remains critical to mitigate revenue concentration and market risks.
• Regulatory and market access barriers need continuous monitoring to sustain growth momentum.

FAQs

1. What is Lexicon's primary revenue-generating product?
Xermelo (telotristat ethyl), approved for carcinoid syndrome diarrhea, accounts for approximately 80% of Lexicon’s revenue[1].

2. Does Lexicon have any late-stage pipeline candidates?
Yes, its pipeline includes investigational drugs for fibrotic diseases and immune-related conditions, aiming to expand beyond the current niche.

3. How does Lexicon’s market share compare to larger biotech firms?
Lexicon holds a small, specialized market share within rare and orphan indications, whereas larger firms like Ipsen and Genentech have broader portfolios and higher revenues.

4. What are the key risks to Lexicon’s growth?
Dependence on a single product, clinical trial failures, market access challenges, and increasing competition threaten its growth prospects.

5. What strategic actions could Lexicon pursue?
Focus on pipeline expansion, deepen existing partnerships, target label extensions, and evaluate acquisitions to diversify revenue streams.

---

References

[1] Lexicon Pharmaceuticals Inc. (2023). Annual Report. Retrieved from https://www.lexpharma.com/investor-relations/financials/